^
    Back
    Association details:
    Biomarker:STRN-ALK fusion
    Cancer:Lung Adenocarcinoma
    Drug:Ensacove (ensartinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Curr Oncol
    Title:

    STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

    Published date:
    09/21/2022
    Excerpt:
    ...we reported a case of lung adenocarcinomas with brain metastasis, harboring STRN-ALK fusion, responded well to ensartinib.
    DOI:
    https://doi.org/10.3390/curroncol29100530